SAN DIEGO -- (Business Wire)
The Board of Directors of Cytori Therapeutics, Inc. (NASDAQ: CYTX)
announced today that Lloyd H. Dean has tendered his resignation as a
member of the Board, effective November 1, 2014. Mr. Dean has served as
a director of the Company since 2010 and served as Chairman of the
Company’s Board of Directors from April 2011 until June 2013.
Mr. Dean said it has been an honor to serve the Company and its
shareholders, but that given his significant imperatives as President
and CEO of Dignity Health, in addition to his ongoing involvement in
healthcare activities at the regional, state and national level, he
would not be able to serve out the remainder of his term.
“Lloyd has made invaluable and impactful contributions to the Board and
to the Company during his five years on the Board. We are thankful for
Lloyd’s leadership over the past five years as the Company has undergone
significant strategic, operational, and financial transformations,” said
Marc Hedrick, M.D., President and Chief Executive Officer of Cytori. “He
brought fresh ideas grounded in his deep knowledge of the healthcare
industry and the real-world dynamic between hospitals and medical
technology companies. We wish him the best in his future endeavors.”
“I am proud of our accomplishments over the past five years as we have
transformed Cytori and taken the lead in regenerative medicine,” said
Mr. Dean. “I am sincerely grateful for the support I've received from
the Board of Directors, our management team, and our stakeholders. I
look forward to seeing the Company continue to grow and successfully
execute on its long-term strategy. While I am transitioning as a member
of the Board, I will remain a fan and shareholder of Cytori.”
About Cytori Therapeutics, Inc.
Cytori Therapeutics, Inc. is developing cell therapies based on
autologous adipose-derived regenerative cells (ADRCs) to treat
cardiovascular disease and repair soft tissue defects. Our scientific
data suggest ADRCs improve blood flow, moderate the immune response and
keep tissue at risk of dying alive. As a result, we believe these cells
can be applied across multiple “ischemic” conditions. These therapies
are made available to the physician and patient at the point-of-care by
Cytori's proprietary technologies and products, including the Celution®
system product family. For more information visit www.cytori.com.
Contacts:
Cytori Therapeutics, Inc.
Tiago Girao, Chief Financial Officer
1-858-458-0900
ir@cytori.com
Source: Cytori Therapeutics, Inc.
© 2024 Canjex Publishing Ltd. All rights reserved.